{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT07331272",
      "orgStudyIdInfo": {
        "id": "LB2404D-0001"
      },
      "organization": {
        "fullName": "Nanjing Legend Biotech Co.",
        "class": "INDUSTRY"
      },
      "briefTitle": "A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)",
      "officialTitle": "An Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)"
    },
    "statusModule": {
      "statusVerifiedDate": "2026-01",
      "overallStatus": "RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2026-01-29",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2028-01-31",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2030-01-31",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2025-12-15",
      "studyFirstSubmitQcDate": "2025-12-30",
      "studyFirstPostDateStruct": {
        "date": "2026-01-09",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2026-01-29",
      "lastUpdatePostDateStruct": {
        "date": "2026-02-02",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Nanjing Legend Biotech Co.",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "This is a prospective, single-arm, open-label and dose-escalation investigator initialed study to evaluate LUCAR-G79D in adult subjects with r/r SLE and r/r IIM.",
      "detailedDescription": "This is a prospective, single-arm, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy profiles of LUCAR-G79D, a chimeric antigen receptor (CAR) -T cell therapy in subjects with r/r SLE and r/r IIM. Patients who meet the eligibility criteria will receive LUCAR-G79D infusion. The study will include the following sequential stages: screening, pre-treatment (lymphodepleting chemotherapy), treatment (LUCAR-G79D infusion) and follow-up."
    },
    "conditionsModule": {
      "conditions": [
        "Systemic Lupus Erythematosus (SLE)",
        "Idiopathic Inflammatory Myopathies(IIM)"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 38,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Chimeric antigen receptor T cells (LUCAR-G79D)",
          "type": "EXPERIMENTAL",
          "description": "Each subject will be given a single-dose LUCAR-G79D cells infusion at each dose level.",
          "interventionNames": [
            "Biological: LUCAR-G79D T cells"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "LUCAR-G79D T cells",
          "description": "Prior to infusion of the LUCAR-G79D T cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.",
          "armGroupLabels": [
            "Chimeric antigen receptor T cells (LUCAR-G79D)"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Incidence, severity, and type of treatment-emergent adverse events (TEAEs)",
          "timeFrame": "2 years after LUCAR-G79D infusion (Day 1)"
        },
        {
          "measure": "Incidence of dose-limiting toxicity (DLT)",
          "timeFrame": "2 years after LUCAR-G79D infusion (Day 1)"
        },
        {
          "measure": "Maximum concentration (Cmax) in peripheral blood",
          "timeFrame": "2 years after LUCAR-G79D infusion (Day 1)"
        },
        {
          "measure": "Time of maximum concentration (Tmax) in peripheral blood",
          "timeFrame": "2 years after LUCAR-G79D infusion (Day 1)"
        },
        {
          "measure": "Area under the concentration-time curve (AUC) in peripheral blood",
          "timeFrame": "2 years after LUCAR-G79D infusion (Day 1)"
        },
        {
          "measure": "Recommended Dose regimen finding",
          "timeFrame": "2 years after LUCAR-G79D infusion (Day 1)"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Change in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores from baseline up to 52 weeks for r/r SLE subjects",
          "description": "SLEDAI-2K is a scale ranging from 0 to 105 points, with higher scores indicating stronger disease activity",
          "timeFrame": "52 weeks after LUCAR-G79D infusion (Day 1)"
        },
        {
          "measure": "Change in manual muscle testing (MMT-8) scores from baseline up to 52 weeks for r/r IIM subjects",
          "description": "MMT-8 is a scale ranging from 0 to 80 points, with higher scores indicating greater preserved muscle strength",
          "timeFrame": "52 weeks after LUCAR-G79D infusion (Day 1)"
        },
        {
          "measure": "Changes from baseline in peripheral blood immunoglobulins from baseline up to 52 weeks for all subjects",
          "description": "Including IgG、IgM、IgA、IgE",
          "timeFrame": "52 weeks after LUCAR-G79D infusion (Day 1)"
        },
        {
          "measure": "Changes from baseline in anti-drug antibody from baseline up to 52 weeks for all subjects",
          "timeFrame": "52 weeks after LUCAR-G79D infusion (Day 1)"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. Subjects voluntary agreement to provide written informed consent.\n2. Aged 18 to 70 years, either sex.\n3. Adequate organ function meet screening criteria.\n4. Positive test for cluster of differentiation antigen 19 (CD19).\n\nSLE:\n\n* Have been diagnosed of SLE at least 6 months before screening.\n* At screening, antinuclear antibody, and/or anti-dsDNA antibody, and/or anti-Smith antibody should be positive.\n* Fulfill relapsed/refractory SLE conditions.\n\nIIM:\n\n* Have been diagnosed of IIM before screening.\n* Positive test for myositis-associated antibodies or myositis-specific antibodies at screening.\n* Fulfill relapsed/refractory IIM conditions.\n\nExclusion Criteria:\n\n1. Active infections such as hepatitis and tuberculosis.\n2. Other autoimmune diseases.\n3. Serious underlying diseases such as tumor, uncontrolled diabetes.\n4. Female subjects who were pregnant, breastfeeding.\n5. Those with a history of major organ transplantation.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "70 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "The Third The People's Hospital of Bengbu",
          "status": "RECRUITING",
          "city": "Bengbu",
          "state": "Anhui",
          "country": "China",
          "contacts": [
            {
              "name": "Hanwei Wang",
              "role": "CONTACT",
              "phone": "860552-3281550",
              "email": "whw2139@sina.com"
            }
          ],
          "geoPoint": {
            "lat": 32.94083,
            "lon": 117.36083
          }
        },
        {
          "facility": "Nanfang Hospital",
          "status": "NOT_YET_RECRUITING",
          "city": "Guangzhou",
          "state": "Guangdong",
          "country": "China",
          "contacts": [
            {
              "name": "Qin Huang",
              "role": "CONTACT",
              "phone": "86020-61641114",
              "email": "qinzihp@foxmail.com"
            }
          ],
          "geoPoint": {
            "lat": 23.11667,
            "lon": 113.25
          }
        },
        {
          "facility": "Xiangya Hospital of Central South University",
          "status": "NOT_YET_RECRUITING",
          "city": "Changsha",
          "state": "Hunan",
          "country": "China",
          "contacts": [
            {
              "name": "Hongjun Zhao",
              "role": "CONTACT",
              "phone": "860731-84327100",
              "email": "hongjunzhao2015@sina.com"
            }
          ],
          "geoPoint": {
            "lat": 28.19874,
            "lon": 112.97087
          }
        },
        {
          "facility": "The Affiliated Hospital of Xuzhou Medical University",
          "status": "RECRUITING",
          "city": "Xuzhou",
          "state": "Jiangsu",
          "country": "China",
          "contacts": [
            {
              "name": "Dongmei Zhou",
              "role": "CONTACT",
              "phone": "860516-85805991",
              "email": "13813283017@163.com"
            }
          ],
          "geoPoint": {
            "lat": 34.20442,
            "lon": 117.28386
          }
        },
        {
          "facility": "The First Affiliated Hospital of Nanchang University",
          "status": "NOT_YET_RECRUITING",
          "city": "Nanchang",
          "state": "Jiangxi",
          "country": "China",
          "contacts": [
            {
              "name": "Rui Wu",
              "role": "CONTACT",
              "phone": "860791-88693035",
              "email": "tcmclinic@163.com"
            },
            {
              "name": "Fei Li",
              "role": "CONTACT",
              "phone": "860791-88692517",
              "email": "ncyf.lifei@outlook.com"
            }
          ],
          "geoPoint": {
            "lat": 28.68396,
            "lon": 115.85306
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D008180",
          "term": "Lupus Erythematosus, Systemic"
        },
        {
          "id": "D009220",
          "term": "Myositis"
        }
      ],
      "ancestors": [
        {
          "id": "D003240",
          "term": "Connective Tissue Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D001327",
          "term": "Autoimmune Diseases"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        },
        {
          "id": "D009135",
          "term": "Muscular Diseases"
        },
        {
          "id": "D009140",
          "term": "Musculoskeletal Diseases"
        },
        {
          "id": "D009468",
          "term": "Neuromuscular Diseases"
        },
        {
          "id": "D009422",
          "term": "Nervous System Diseases"
        }
      ]
    }
  },
  "hasResults": false
}